Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
This study aimed to determine the effects of nine OPRM1, OPRD1 and OPRK1 polymorphisms on plasma BUP and norbuprenorphine (norBUP) concentrations and various treatment responses in a sample of 122 patients receiving BUP/naloxone. Plasma concentrations of BUP and norBUP were detected by LC-MS/MS. PCR-RFLP method was used to genotype polymorphisms. OPRD1 rs569356 GG had significantly lower plasma norBUP concentration (p = 0.018), dose- (p = 0.049) and dose/kg-normalized norBUP values (p = 0.036) compared with AA. Craving and withdrawal symptoms were significantly higher in OPRD1 rs569356 AG+GG relative to AA. There was a statistically significant difference between the OPRD1 rs678849 genotypes in the intensity of anxiety (13.5 for CT+TT and 7.5 for TT). OPRM1 rs648893 TT (18.8 ± 10.8) was significantly different to CC+CT (14.82 ± 11.3; p = 0.049) in view of the intensity of depression. This current study provides the first data on a prominent effect of the OPRD1 rs569356 variation on BUP pharmacology due to its metabolite norBUP.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.etap.2023.104143 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of PDYN 68-bpVNTR, BDNF rs6265, OPRD1 rs569356 and OPRM1 rs2075572 polymorphisms on opioid-methamphetamine co-use.
Environ Toxicol Pharmacol
June 2025
Ankara University, Institute of Forensic Sciences, Ankara, Turkiye. Electronic address:
To investigate the impact of PDYN 68-bpVNTR, BDNF rs6265, OPRD1 rs569356 and OPRM1 rs2075572 variations on the susceptibility to opioid-methamphetamine co-use, a total of 532 individuals, including opioid (n = 104), and methamphetamine (n = 166) users as well as opioid and methamphetamine co- users (n = 158) and healthy individuals (n = 104), were included. BDNF rs6265, OPRD1 rs569356 and OPRM1 rs2075572 were genotyped by PCR-RFLP method, while PDYN 68-bp VNTR was genotyped by PCR. The assessment of impulsiveness, craving, withdrawal, anxiety and depressive symptoms was conducted using scales.
View Article and Find Full Text PDFOPRD1 rs569356 polymorphism has an effect on plasma norbuprenorphine levels and dose/kg-normalized norbuprenorphine values in individuals with opioid use disorder.
Environ Toxicol Pharmacol
June 2023
Ankara Training and Research Hospital AMATEM Clinic, Ankara, Turkiye.
This study aimed to determine the effects of nine OPRM1, OPRD1 and OPRK1 polymorphisms on plasma BUP and norbuprenorphine (norBUP) concentrations and various treatment responses in a sample of 122 patients receiving BUP/naloxone. Plasma concentrations of BUP and norBUP were detected by LC-MS/MS. PCR-RFLP method was used to genotype polymorphisms.
View Article and Find Full Text PDFOPRD1 Genetic Variation and Human Disease.
Handb Exp Pharmacol
January 2019
Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, UK.
The OPRD1 gene encodes the delta-opioid receptor, which has multiple functions including regulating reward pathways. The gene contains more than 2,000 verified genetic variants but only 2 currently have evidence for specific functions: rs1042114 disrupts maturation of the receptor and rs569356 affects OPRD1 expression. These polymorphisms and others in the gene have been found to be associated with human diseases.
View Article and Find Full Text PDFFunctional impact of a single-nucleotide polymorphism in the OPRD1 promoter region.
J Hum Genet
May 2010
Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
The delta-opioid receptor mediates rewarding effects of many substances of abuse. We reported an increased frequency of the minor G-allele of single-nucleotide polymorphism (SNP) rs569356 (the only variant identified so far in the promoter region of the delta-opioid receptor gene (OPRD1)) in subjects with opioid dependence. In this study, we examined the functional significance of this variant.
View Article and Find Full Text PDF